Duchenne News Tags: Edgewise

Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Edgewsie announces positive 6-moth interim results from the ARCH study

September 12, 2022

Edgewise Announces Positive EDG-5506 4-Month Interim ARCH Data in BMD

On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.

September 7, 2022

Edgewise Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506

On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth quarter of 2022.

July 14, 2022

Edgewise Therapeutics Announces Initiation of CANYON Phase 2 Clinical Trial Evaluating EDG-5506

On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular dystrophy.

June 21, 2022

Edgewise Therapeutics Announces Positive Results from the ARCH Open Label Study of EDG-5506

On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Sitemap

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Programs

Events